ADOLESCENT ENDOMETRIOSIS



. Nermeen Shams-Eldin

A.Professor of Obstetrics & Gynecology

Faculty of medicine – Mansoura University

Outline

• Overview on adolescent endometriosis.

• Diagnosis of adolescent endometriosis.

• Treatment of adolescent endometriosis.

• Role of fertility preservation.

Adolescent Endometriosis; An overview

Definition

Presence of histological elements like endometrial

glands & stroma outside the uterine cavity,

affecting girls <20 years.

(Brosens et al., 2013)

Incidence & Etiology

• Actual incidence is unknown & varies from 25-73%.

(Brosens et al., 2013)

• It was described in post-thelarcheal girls not only postmenarcheal girls suggesting multifactorial peripubertal etiologies not only retrograde menstruation.

(Shah & Missmer, 2011)

Main risk factors

- Positive family history.
- Genital malformations leading to outflow obstructions.
- Early age of menarche.
- Short menstrual cycle.

(Yang et al., 2012); (Geysenbergh et al., 2017)

Diagnosis of adolescent endometriosis

Diagnosis

Endometriosis may be more progressive than in adults with

variable manifestations, with consideration to risk factors.

 It should be differentiated from: Adenomyosis, Recurrent Infections, Gastrointestinal Pathologies (as IBS), Mullerian Anomalies that totally or partially obstruct the flow.

(Benagiano et al., 2018)

Diagnosis

Unlike endometriosis in adults, adolescent endometriosis often manifests in the form of stage I or II, characterized by superficial peritoneal disease & less frequently as stage III or IV, which can involve deeply infiltrative disease

(Tyson et al., 2024)



AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE REVISED CLASSIFICATION OF ENDOMETRIOSIS

Patient's Name Stage I (Minimal) - 1-5 Stage II (Mild) - 6-15 Stage III (Moderate) - 16-40 Stage IV (Severe) - >40 Total		Date Laparoscopy Laparotomy Photography Recommended Treatment Prognosis			
PERITONEUM	ENDOMETRIOSIS	<1cm	1-3cm	>3cm	
	Superficial	1	2	4	
	Deep	2	1	6	
OVARY	R Superficial	1	2	4	
	Deep	4	16	20	
	L Superficial	1	2	4	
	Deep	4	16	20	
	POSTERIOR CULDESAC OBLITERATION	Partial		Complete	
		4 40		40	
OVARY	ADHESIONS	<1/3 Enclosure	1/3-2/3 Enclosure	> 2/3 Enclosure	
	R Filmy	1	2	4	
	Dense	4	8	16	
	L Filmy	1	2	4	
	Dense	4	8	16	
TUBE	R Filmy	1	2	4	
	Dense	4*	8.	16	
	L Filmy	1	2	4	
	Dense	4.	8*	16	

If the fimbriated end of the fallopian tube is completely enclosed, change the point assignment to 16.

Denote appearance of superficial implant types as red [(R), red, red-pink, flamelike, vesicular blobs, cfear vesicles], white <math>[(W), opacifications, peritoneal defects, yellow-brown], or black <math>[(R) black, hemosiderin deposits, blue]. Denote percent of total described as R $_$ %, W $_$ % and B $_$ %. Total should equal 100%.



Associated Patholog To Be Used with Abnormal Tubes and/or Ovaries

Symptoms

- Cyclic or acyclic pelvic pain.
- Ovulatory pain.
- Premenstrual spotting.
- Dysuria, Dyschasia or Bowel symptoms.
- Systemic symptoms during menses (including nausea/stomach upset or dizziness/headache).
- Consider also dysparunia for married females.

Clinical examination

- No evidence was found with regard to best method of clinical examination (abdominal, local) in adolescents.
- But acceptance is necessary for vaginal/rectal examination to be discussed with the adolescent and her

caregiver (ESHRE 2022, GPP).

(Becker et al., 2022)

Imaging

- TVS is recommended to be used in adolescents in whom it is appropriate, as it is effective in diagnosing ovarian endometriosis.
- If TVS scanning is not appropriate, transabdominal, transperineal, or transrectal scan, 3D ultrasound, or MRI may be considered (ESHRE 2022, Grade I).

Ultrasonographic image of nodule affecting USL



(Martire et al., 2024)

TVS/Doppler image of endometrioma in a 19-year-old female with pelvic pain



(Back et al., 2017)



- Showed low diagnostic value.
- CA125 was studied in surgically confirmed cases & its level didn't vary between control & cases.

(Sasamoto et al., 2020)

Laparoscopy

- Needed in cases of persistent symptoms & failed medical treatment &/or negative imaging.
- Lesions are not the same as in adult type, being more towards atypical red or clear vesicular lesions, however, extensive adhesions or endometrioma may be present.

Laparoscopic images showing red, inflamed adolescent endometriotic implant in right paraovarian fossa & clear, vesicular lesion





Histopathology

- If laparoscopy is performed, biopsy should be obtained.
- In a systematic review, by Janssen et al, they assessed 15 studies
 - by laparoscopy after chronic pelvic pain & dysmenorrhea in
 - which 880 adolescents(10-21 years) were not responding to OCP

or NSAIDS, endometriosis was detected in two thirds of them.

(Janssen et al., 2013)

Histopathology

- Prevalence of adolescent girls with ASRM stages III & IV endometriosis was 32% & 16%, respectively in cases with resistant chronic pelvic pain.
- Histopathology was not performed in all studies, but if done,

detection rate was between 43% & 100% in different studies.

(Janssen et al., 2013)

Treatment of adolescent endometriosis

Treatment

- The aims are to suppress pain & prevent disease progression.
- The main lines are:
 - **1- Medical treatment.**
 - **2- Surgical treatment.**
 - **3- Combined medical & surgical treatment.**

- There are few studies about effective treatment in adolescents & it is needed to tailor treatment to achieve good quality of life.
- The role of NSAIDS (or other analgesics) is to relieve pain, dysmenorrhea.

(Becker et al., 2022)

Hormonal contraceptives or progestins had been advised

for endometriosis-associated pain.

(Becker et al., 2022)

• Less pain was reported with use of OCP than placebo.

(Sarıdogan et al., 2017)

• Continuous rather than cyclic oral, vaginal, or estro-progestinic

patch therapy is preferred to achieve an adequate atrophy & decidualization of the endometriotic lesions.

• If there is no symptom relief after 4 months of continuative empiric therapy, a surgical approach could be suggested.

(Sarıdogan et al., 2017)

- Progestins suppress the pituitary-ovarian axis, causing anovulation & atrophy of the eutopic & ectopic endometria.
- They also reduce inflammation by modulating immune response.
- Either oral progestins (Dienogest, Norethindrone acetate), Etonogestrel implant or LNG-IUS can be used.

(Ebert et al., 2017)

- It was concluded that Dienogest (2mg/day) is as effective
 - for endometriosis-associated pain in adolescents as in
 - adults.

(Ebert et al., 2017)

• LNG-IUS role was investigated & it was effective.

(Yoost et al., 2013)

• **Danazol** has limited use due to its androgenic effects.

(Yoost et al., 2013)

 GnRH agonists :After one year of treatment, quality of life was improved as compared to baseline, but it is not preferred in females < 16 year due to its effect on BMD; and It is used only if other treatments have failed.

(Sadler Gallagher et al., 2017)

Surgical treatment

- Surgery should only be performed in clinically necessary cases, such as in young patients who are not responding to medical therapy or suspect malignant ovarian cyst.
- It should be performed laparoscopically by an experienced surgeon.

Surgical treatment

• No data exist to show that ablation or excision is superior for the

treatment of superficial peritoneal disease (some surgeons hypothesize that both can lead to adhesion formation).

• Experts encourage caution when generalizing the positive outcomes of excisional surgery for stage III & IV disease.

Surgical treatment

- Although endometriomas are less frequent in adolescent, the goal of surgery in adolescents should be to perform cystectomy, rather than simply draining the cyst & CO2 laser vaporisation.
- Recurrence rates may be considerable (recurrence of ovarian cysts & pain after surgery is 40-50% at 5-year follow-up), especially when surgery is not followed by hormone treatment.

(ACOG, 2018)

Combined medical & surgical treatment

It was suggested that long-term GnRH agonists & OCP for

6-12 month after conservative surgery will help to prevent

recurrence.

(Seo et al, 2017)

Fertility preservation

in adolescent endometriosis

Fertility preservation

• There is increased risk of premature ovarian failure.

• In opinion papers, fertility preservation may be indicated for

those with bilateral ovarian endometriomas and those operated

unilaterally with a contralateral recurrence.

(Somigliana et al., 2015); (Carrillo et al., 2016)

Fertility preservation

- Patients should be informed about fertility preservations options, however; benefit, safety & indication remain unknown.
- It may be beneficial for young women with endometriosis & if considered, it should be done before ovarian surgery is carried out.

Key messages

- Adolescent endometriosis is multifactorial with widely variable incidence.
- It often manifests as stage I or II & less frequently as stage III or IV.
- It may be more progressive than in adults with variable manifestations.
- TVS is the recommended imaging for diagnosis, if appropriate.
- Laparoscopy is needed in persistent symptoms & failed medical treatment &/or negative imaging.
- If laparoscopy is performed, biopsy should be obtained.
- Treatment aims to suppress pain & prevent disease progression.

Key messages

- Recommended medical treatments include hormonal contraceptives, progestins or GnRHa.
- Surgery should only be performed in non-responders to medical therapy or suspected malignancy.
- Surgery should be performed via laparoscopy by an experienced surgeon.
- **Combined** medical & surgical treatment may help to prevent recurrence.
- Fertility preservation options exist & patients should be informed about them, however; benefit, safety & indication remain unknown.

References

- ACOG Committee Opinion No. 760: Dysmenorrhea and Endometriosis in the Adolescent. Obstet Gynecol. 2018 Dec;132(6):e249-e258.
- Back SJ, Maya CL, Zewdneh D, Epelman M. Emergent ultrasound evaluation of the pediatric female pelvis. *Pediatr Radiol. 2017* Aug;47(9):1134-1143.
- Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel L, King K, Kvaskoff M, Nap A, Petersen K, Saridogan E, Tomassetti C, van Hanegem N, Vulliemoz N, Vermeulen N; ESHRE Endometriosis Guideline Group. ESHRE guideline: endometriosis. *Hum Reprod Open. 2022 Feb 26;2022(2):hoac009.*
- Benagiano G, Guo SW, Puttemans P, Gordts S, Brosens I. Progress in the diagnosis and management of adolescent endometriosis: an opinion. *Reprod Biomed Online*. 2018 Jan;36(1):102-114.
- Brosens I, Gordts S, Benagiano G. Endometriosis in adolescents is a hidden, progressive and severe disease that deserves attention, not just compassion. *Hum Reprod. 2013 Aug;28(8):2026-31*.
- Carrillo L, Seidman DS, Cittadini E, Meirow D. The role of fertility preservation in patients with endometriosis. J Assist Reprod Genet. 2016 Mar;33(3):317-323.
- Ebert AD, Dong L, Merz M, Kirsch B, Francuski M, Böttcher B, Roman H, Suvitie P, Hlavackova O, Gude K, Seitz C. Dienogest 2 mg Daily in the Treatment of Adolescents with Clinically Suspected Endometriosis: The VISanne Study to Assess Safety in ADOlescents. J Pediatr Adolesc Gynecol. 2017 Oct;30(5):560-567.
- Geysenbergh B, Dancet EAF, D'Hooghe T. Detecting Endometriosis in Adolescents: Why Not Start from Self-Report Screening Questionnaires for Adult Women? *Gynecol Obstet Invest. 2017;82(4):322-328.*
- Greene R, Stratton P, Cleary SD, Ballweg ML, Sinaii N. Diagnostic experience among 4,334 women reporting surgically diagnosed endometriosis. *Fertil Steril. 2009 Jan;91(1):32-9.*
- Janssen EB, Rijkers AC, Hoppenbrouwers K, Meuleman C, D'Hooghe TM. Prevalence of endometriosis diagnosed by laparoscopy in adolescents with dysmenorrhea or chronic pelvic pain: a systematic review. *Hum Reprod Update. 2013 Sep-Oct;19(5):570-82.*

References

- Martire FG, Giorgi M, D'Abate C, Colombi I, Ginetti A, Cannoni A, Fedele F, Exacoustos C, Centini G, Zupi E, Lazzeri L. Deep Infiltrating Endometriosis in Adolescence: Early Diagnosis and Possible Prevention of Disease Progression. J Clin Med. 2024 Jan 18;13(2):550.
- Revised American Society for Reproductive medicine classification of endometriosis. *Fertile Sterile .1997, 67(5); 817-21.*
- Sadler Gallagher J, Feldman HA, Stokes NA, Laufer MR, Hornstein MD, Gordon CM, DiVasta AD. The Effects of Gonadotropin-Releasing Hormone Agonist Combined with Add-Back Therapy on Quality of Life for Adolescents with Endometriosis: A Randomized Controlled Trial. J Pediatr Adolesc Gynecol. 2017 Apr;30(2):215-222.
- Sarıdoğan E. Adolescent endometriosis. Eur J Obstet Gynecol Reprod Biol. 2017 Feb;209:46-49.
- Sasamoto N, DePari M, Vitonis AF, Laufer MR, Missmer SA, Shafrir AL, Terry KL. Evaluation of CA125 in relation to pain symptoms among adolescents and young adult women with and without surgically-confirmed endometriosis. *PLoS One. 2020 Aug 24;15(8):e0238043.*
- Seo JW, Lee DY, Yoon BK, Choi D. The Efficacy of Postoperative Cyclic Oral Contraceptives after Gonadotropin-Releasing Hormone Agonist Therapy to Prevent Endometrioma Recurrence in Adolescents. J Pediatr Adolesc Gynecol. 2017 Apr;30(2):223-227.
- Shah DK, Missmer SA. Scientific investigation of endometriosis among adolescents. J Pediatr Adolesc Gynecol. 2011 Oct;24(5 Suppl):S18-9.
- Somigliana E, Viganò P, Filippi F, Papaleo E, Benaglia L, Candiani M, Vercellini P. Fertility preservation in women with endometriosis: for all, for some, for none? *Hum Reprod. 2015 Jun;30(6):1280-6.*
- Tyson N, Shim J, Lee T, King CR, Einarsson J, Hornstein MD, Laufer MR. Surgical Considerations in the Management of Adolescent Endometriosis-An Expert Commentary. J Minim Invasive Gynecol. 2024 May;31(5):378-386.
- Yang Y, Wang Y, Yang J, Wang S, Lang J. Adolescent endometriosis in China: a retrospective analysis of 63 cases. J Pediatr Adolesc Gynecol. 2012 Oct;25(5):295-9.
- Yoost J, LaJoie AS, Hertweck P, Loveless M. Use of the levonorgestrel intrauterine system in adolescents with endometriosis. J Pediatr Adolesc Gynecol. 2013 Apr;26(2):120-4.

